BRPI0915460A2 - métodos e composições para a liberação intensificada de macromoléculas - Google Patents
métodos e composições para a liberação intensificada de macromoléculasInfo
- Publication number
- BRPI0915460A2 BRPI0915460A2 BRPI0915460A BRPI0915460A BRPI0915460A2 BR PI0915460 A2 BRPI0915460 A2 BR PI0915460A2 BR PI0915460 A BRPI0915460 A BR PI0915460A BR PI0915460 A BRPI0915460 A BR PI0915460A BR PI0915460 A2 BRPI0915460 A2 BR PI0915460A2
- Authority
- BR
- Brazil
- Prior art keywords
- macromolecules
- compositions
- methods
- enhanced release
- enhanced
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7958608P | 2008-07-10 | 2008-07-10 | |
| PCT/CH2009/000248 WO2010003268A2 (en) | 2008-07-10 | 2009-07-10 | Methods and compositions for enhanced delivery of macromolecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0915460A2 true BRPI0915460A2 (pt) | 2015-11-10 |
Family
ID=41328751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0915460A BRPI0915460A2 (pt) | 2008-07-10 | 2009-07-10 | métodos e composições para a liberação intensificada de macromoléculas |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8697074B2 (pt) |
| EP (2) | EP2303230A2 (pt) |
| JP (2) | JP5579713B2 (pt) |
| KR (1) | KR20110031373A (pt) |
| CN (2) | CN102088958A (pt) |
| BR (1) | BRPI0915460A2 (pt) |
| CA (1) | CA2730178A1 (pt) |
| HK (1) | HK1201201A1 (pt) |
| MX (1) | MX2011000009A (pt) |
| RU (1) | RU2522245C2 (pt) |
| WO (1) | WO2010003268A2 (pt) |
| ZA (1) | ZA201008597B (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101842388B (zh) * | 2007-09-13 | 2013-09-04 | 德勒尼克斯治疗股份公司 | 针对β淀粉样肽的人源化抗体 |
| HUE032894T2 (hu) * | 2008-06-25 | 2017-11-28 | Esbatech Alcon Biomed Res Unit | VEGF-gátló, stabilis és oldható antitestek |
| RU2653753C1 (ru) | 2008-06-25 | 2018-05-14 | ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи | СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα |
| US8697074B2 (en) | 2008-07-10 | 2014-04-15 | Esbatech, An Alcon Biomedical Research Unit Llc | Methods and compositions for enhanced delivery of macromolecules |
| AR083495A1 (es) * | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
| ES2843724T3 (es) * | 2015-11-30 | 2021-07-20 | Inst Nat Sante Rech Med | Antagonistas de NMDAR para el tratamiento de la angiogénesis tumoral |
| JP6978427B2 (ja) | 2016-03-17 | 2021-12-08 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 抗ＴＮＦα抗体とその機能性フラグメント |
| EP3219726B1 (en) | 2016-03-17 | 2020-12-02 | Tillotts Pharma AG | Anti-tnf alpha-antibodies and functional fragments thereof |
| US10787508B2 (en) | 2016-03-17 | 2020-09-29 | Numab Innovation Ag | Anti-TNFα-antibodies and functional fragments thereof |
| RS61412B1 (sr) | 2016-03-17 | 2021-03-31 | Tillotts Pharma Ag | Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti |
| BR112018017165A2 (pt) | 2016-03-17 | 2019-01-02 | Numab Innovation Ag | anticorpos anti-tnf-alfa e fragmentos funcionais dos mesmos |
| MA45684A (fr) | 2016-07-14 | 2019-05-22 | Bioarctic Neuroscience Ab | Protéine d'apport du cerveau |
| EP3409688A1 (en) | 2017-05-31 | 2018-12-05 | Tillotts Pharma Ag | Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof |
| EP3456739A1 (en) | 2017-09-19 | 2019-03-20 | Tillotts Pharma Ag | Use of anti-tnfalpha antibodies for treating wounds |
| ES2938609T3 (es) | 2017-09-20 | 2023-04-13 | Tillotts Pharma Ag | Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión |
| EP3459527B1 (en) | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization |
| EP3459529A1 (en) | 2017-09-20 | 2019-03-27 | Tillotts Pharma Ag | Preparation of sustained release solid dosage forms comprising antibodies by spray drying |
| WO2020114616A1 (en) | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof |
| IL320091A (en) | 2019-01-31 | 2025-06-01 | Numab Therapeutics AG | Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof |
| EP4132579A4 (en) | 2020-04-10 | 2024-05-22 | Invivyd, Inc. | CORONAVIRUS S-PROTEIN SPECIFIC COMPOUNDS AND USES THEREOF |
| CN120981225A (zh) | 2023-03-28 | 2025-11-18 | 蒂洛特斯制药股份有限公司 | 用于在下部胃肠道中缓释的包含抗体的固体口服剂型 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5534496A (en) * | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| PT746294E (pt) * | 1993-10-07 | 2005-03-31 | Odontex Inc | Promotores de absorcao para formulacoes farmaceuticas topicas |
| US20040156824A1 (en) | 1996-12-23 | 2004-08-12 | Epstein Alan L. | Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof |
| DE69936927T2 (de) * | 1998-10-21 | 2008-05-15 | Altor Bioscience Corp., Miramar | Polyspezifische bindemoleküle und deren verwendung |
| US7214658B2 (en) * | 2004-07-06 | 2007-05-08 | Tact Ip, Llc | Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection |
| JP2003528939A (ja) | 1999-09-03 | 2003-09-30 | スクール オブ ファーマシー， ユニヴァーシティ オブ ロンドン | 分解性ポリマー |
| EP1222217B1 (en) | 1999-09-08 | 2005-06-15 | Polytherics Limited | Uniform molecular weight polymers |
| ES2270893T3 (es) | 1999-12-24 | 2007-04-16 | Genentech, Inc. | Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos. |
| DK2322631T3 (en) | 2001-04-19 | 2015-01-12 | Scripps Research Inst | Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar |
| GB0131112D0 (en) | 2001-12-31 | 2002-02-13 | Univ London Pharmacy | Block copolymers |
| GB0209022D0 (en) | 2002-04-19 | 2002-05-29 | Imp College Innovations Ltd | Compounds |
| EP2332989B1 (en) | 2002-05-22 | 2015-04-01 | ESBATech, an Alcon Biomedical Research Unit LLC | Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same |
| CA2501091A1 (en) | 2002-10-01 | 2004-04-15 | Northwestern University | Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof |
| AU2003201499B2 (en) * | 2003-01-10 | 2011-06-02 | Centro De Investigacion Y De Estudios Avanzados Del Instituto Politecnico Nacional | Employment of rotavirus proteins, derived proteins and peptides for the modulation of tissue permeability |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| GB0400264D0 (en) | 2004-01-07 | 2004-02-11 | Polytherics Ltd | Complexes |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| US20090136505A1 (en) * | 2005-02-23 | 2009-05-28 | Johanna Bentz | Intranasal Administration of Active Agents to the Central Nervous System |
| US7431927B2 (en) * | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
| JP5089582B2 (ja) | 2005-06-07 | 2012-12-05 | エスバテック、アン アルコン バイオメディカル リサーチ ユニット、エルエルシー | ＴＮＦαを阻害する安定な可溶性抗体 |
| JP2009506983A (ja) * | 2005-06-28 | 2009-02-19 | ザ・スクリプス・リサーチ・インステイチユート | ファージベクターを用いた中枢神経系への活性タンパク質の送達 |
| DK2046382T3 (en) * | 2006-07-10 | 2016-12-12 | Esbatech Alcon Biomed Res Unit | scFv Antibodies which passes through the epithelial and / or endothelial layer |
| AU2008267733B2 (en) | 2007-06-25 | 2013-11-14 | Esbatech, An Alcon Biomedical Research Unit Llc | Sequence based engineering and optimization of single chain antibodies |
| RU2653753C1 (ru) | 2008-06-25 | 2018-05-14 | ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи | СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα |
| CN104004094B (zh) * | 2008-06-25 | 2017-09-22 | 艾斯巴技术-诺华有限责任公司 | 使用通用抗体构架进行的兔抗体的人源化 |
| MX344076B (es) * | 2008-06-30 | 2016-12-05 | Esbatech Alcon Biomed Res Unit | Polipeptidos funcionalizados. |
| US8697074B2 (en) | 2008-07-10 | 2014-04-15 | Esbatech, An Alcon Biomedical Research Unit Llc | Methods and compositions for enhanced delivery of macromolecules |
-
2009
- 2009-07-10 US US13/000,533 patent/US8697074B2/en active Active
- 2009-07-10 EP EP09775745A patent/EP2303230A2/en not_active Withdrawn
- 2009-07-10 KR KR1020117002959A patent/KR20110031373A/ko not_active Ceased
- 2009-07-10 MX MX2011000009A patent/MX2011000009A/es active IP Right Grant
- 2009-07-10 WO PCT/CH2009/000248 patent/WO2010003268A2/en not_active Ceased
- 2009-07-10 BR BRPI0915460A patent/BRPI0915460A2/pt not_active IP Right Cessation
- 2009-07-10 CA CA2730178A patent/CA2730178A1/en not_active Abandoned
- 2009-07-10 JP JP2011516941A patent/JP5579713B2/ja active Active
- 2009-07-10 CN CN2009801262475A patent/CN102088958A/zh active Pending
- 2009-07-10 EP EP14162656.4A patent/EP2769711A1/en not_active Withdrawn
- 2009-07-10 CN CN201510138310.4A patent/CN104800147A/zh active Pending
- 2009-07-10 RU RU2011104816/15A patent/RU2522245C2/ru not_active Application Discontinuation
-
2010
- 2010-11-30 ZA ZA2010/08597A patent/ZA201008597B/en unknown
-
2014
- 2014-02-12 JP JP2014024529A patent/JP2014122230A/ja not_active Withdrawn
- 2014-02-26 US US14/190,788 patent/US20140212421A1/en not_active Abandoned
-
2015
- 2015-02-18 HK HK15101810.9A patent/HK1201201A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102088958A (zh) | 2011-06-08 |
| CN104800147A (zh) | 2015-07-29 |
| JP2014122230A (ja) | 2014-07-03 |
| US20140212421A1 (en) | 2014-07-31 |
| CA2730178A1 (en) | 2010-01-14 |
| MX2011000009A (es) | 2011-08-15 |
| WO2010003268A2 (en) | 2010-01-14 |
| RU2522245C2 (ru) | 2014-07-10 |
| AU2009267729A1 (en) | 2010-01-14 |
| US20110135644A1 (en) | 2011-06-09 |
| EP2303230A2 (en) | 2011-04-06 |
| RU2011104816A (ru) | 2012-08-20 |
| WO2010003268A3 (en) | 2011-01-13 |
| ZA201008597B (en) | 2012-05-30 |
| US8697074B2 (en) | 2014-04-15 |
| JP5579713B2 (ja) | 2014-08-27 |
| JP2011527289A (ja) | 2011-10-27 |
| HK1201201A1 (en) | 2015-08-28 |
| EP2769711A1 (en) | 2014-08-27 |
| KR20110031373A (ko) | 2011-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0915460A2 (pt) | métodos e composições para a liberação intensificada de macromoléculas | |
| BRPI0909780A2 (pt) | Composições e métodos para liberação de fármaco | |
| CY2019005I2 (el) | Συνθεσεις και μεθοδοι για την αναστολη εκφρασης τρανσθυρετινης | |
| BRPI1012525A2 (pt) | composições de nanopatículas isentas de príons e métodos para sua fabricação | |
| BRPI0919466A2 (pt) | composição farmacêutica para liberação modificada | |
| PT2655370T (pt) | Composições e métodos para a modulação de fxr | |
| BRPI0918971A2 (pt) | tienopirimidinas para composições farmacêuticas | |
| BRPI0820980A2 (pt) | Composições e métodos para detecção de tiabs | |
| PT2144998T (pt) | Métodos e composições para vírus vivos atenuados | |
| BRPI0921959A2 (pt) | métodos e composições para remoção de tatuagem | |
| BRPI0906739A2 (pt) | Métodos e composições relacionadas para internalizar peptídeos de rgd | |
| BR112013014395A2 (pt) | evento de soja syht0h2 e composições e métodos para deteção desses | |
| BRPI1012148A2 (pt) | método e equipamento para preparar dentadura | |
| HUE065114T2 (hu) | Monoklórtrifluorpropén vegyületek és készítmények és eljárások azok alkalmazásával | |
| BRPI0914300A2 (pt) | composições e métodos para imunogenicidade intensificada de somatostatina | |
| BRPI0908379A2 (pt) | sistemas e métodos para obter dentaduras customizadas | |
| BRPI0918652A2 (pt) | Composições farmacêuticas e métodos de libração relacionadas. | |
| ES2580777T8 (es) | Composición farmacéutica sólida que comprende amlodipino y losartán y procedimiento para producir la misma | |
| PL2356462T3 (pl) | Kompozycje anty-CXCR1 oraz sposoby | |
| BRPI0912703A2 (pt) | composições imuno-moduladoras e métodos para uso dessas | |
| BR112012002335A2 (pt) | pigmento composto e método para preparação do mesmo | |
| FI20096058A0 (fi) | Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä | |
| BRPI1007600A2 (pt) | composições e métodos para tratamento de doenças cardiovasculares | |
| PT2512502T (pt) | Métodos e composições para supressão de tumores | |
| BRPI1008326A2 (pt) | Composições e métodos para controlar nanatódeos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |